Recent advances in neonatology

Foreword
Although this article is published in the Fetal and Neonatal Edition, it was originally commissioned to be of interest to general paediatricians who are not specialists in neonatology, but who are responsible for the provision of much of the UK's neonatal care.

Introduction
Neonatal medicine continues to make rapid progress. Babies born at 26 weeks of gestation now have a better than even chance of survival, a remarkable improvement compared to even a decade ago. The combination of antenatal steroids and postnatal surfactant has significantly reduced mortality and the risk of intracranial haemorrhage. Artificial ventilators have become more and more sophisticated and the role of high frequency oscillation (HFOV) as rescue treatment is now established. Infections still contribute to many premature labours, and although the results of the ORACLE trial are still awaited, intrapartum antibiotic prophylaxis against neonatal group B streptococcal infection is gaining widespread acceptance. For term infants with persistent pulmonary hypertension (PPHN), nitric oxide (NO) has made a rapid leap from the laboratory to the cotside and has already proved to be effective treatment.

This review aims to provide a brief update of the most important recent changes in neonatal medicine.

Surfactant treatment
Exogenous surfactant has now been in use for nearly a decade. Surfactant reduces neonatal mortality from respiratory distress syndrome (RDS) by about 40% and reduces complications like air leaks by up to 60%. The combination of postnatal surfactant with antenatal steroids is more effective than either treatment alone. Surfactant treatment has no effect against chronic lung disease (CLD), gross maternal haemorrhage–intraventricular haemorrhage (GMH–IVH), and patent ductus arteriosus (PDA). The controversies that remain are not to do with surfactant use in typical RDS, but are about which product is superior; whether there is a lower gestation or weight limit at which surfactant should be withheld; and the choice between rescue and prophylactic treatment. Indications for surfactant use in conditions other than RDS, such as meconium aspiration syndrome, are beginning to emerge.

PROPHYLAXIS VS RESCUE TREATMENT
Now that it is accepted surfactant improves the outlook for neonatal RDS, the critical issue is timing. The simple answer seems to be that treatment should be given as early as possible, once a preterm baby is intubated, and ideally within the first few breaths of life. Seven randomised controlled trials have compared surfactant treatment at birth (prophylaxis) with treatment a few hours later (rescue). Prophylaxis was more effective than rescue treatment. The odds ratios (95% confidence intervals) in favour of prophylaxis were 0.59 (0.46 to 0.76) for neonatal mortality, 0.62 (0.42 to 0.89) for pneumothoraces, and 0.54 (0.36 to 0.82) for pulmonary interstitial emphysema. Current recommendations are to give prophylactic surfactant to all babies who are intubated for resuscitation at less than 32 weeks of gestation.

Later administration of surfactant will be beneficial in larger infants who develop RDS, and in some trials the first treatment has been as late as 72 hours after birth. There is little evidence to support surfactant administration beyond this time. Multiple doses are better than a single dose for infants who remain ventilated.

Where infants are to be transferred, surfactant should still be administered as early as possible and before transfer. However, it is important that those using this treatment are familiar with the rapid changes in ventilator requirements which often follow the administration of natural surfactants. There is no evidence that harm has been done by giving either natural or synthetic surfactant. There is a practical problem with one or two of the surfactants as they involve delivering large volumes into the trachea, and a divided dose may be necessary. The answer would be to use a method or a product where this is not an issue, but the ideal solution to this problem has yet to be found.

NATURAL VS SYNTHETIC SURFACTANT
Four surfactants are licensed in the UK for treating babies. They are animal derived and synthetic surfactants. The animal derived surfactants comprise Curosurf, which is an extract of pig lung mince and given in a volume of 1.25 to 2.5 ml/kg, and Survanta, an extract of cow lung mince with three added lipids, given as a dose of 4 ml/kg. These surfactants contain the apoproteins SP-B and SP-C, and these are thought to enhance their properties. The synthetic surfactants comprise Exosurf, a mixture of the key phospholipid DPPC, hexadecanol, and tyloxapol, given in a volume of 5 ml/kg, and ALEC, a mixture of DPPC and phosphatidylglycerol, given as a dose of 1.2 ml, regardless of size.

Fifteen studies have compared different surfactants, seven of which were of suitable quality for meta-analysis. Six of these trials compared Survanta and Exosurf; the other trial compared Infasurf and Exosurf. The meta-analyses support a significant reduction in the risk of pneumothorax (0.69 CI 0.57 to 0.85), and showed a non-significant trend towards reduced mortality. Soll's conclusion was that: “on clinical grounds, natural surfactant extracts were the more desirable choice.” The onset of action is more rapid with animal derived surfactants than with artificial surfactants. This means that the babies treated with these surfactants need to be carefully monitored and their ventilator settings adjusted appropriately. Concern has been expressed because rapid effects lead to temporary changes in cerebral blood flow velocity and EEG recordings. There is currently no evidence to suggest that this more rapid onset of action has any deleterious effects.

UPPER AND LOWER GESTATIONAL AGE LIMITS FOR SURFACTANT TREATMENT
Although the data are limited due to small numbers in trials, the data that can be extracted show benefit for the smallest of babies. Gestational or weight limits for
either giving or withholding surfactant are not helpful, and may deprive babies who could benefit from surfactant use.

INDICATIONS FOR SURFACTANT USE IN OTHER CONDITIONS
There have been several small trials on the use of surfactant outside the classic indication of RDS, such as sepsis, pulmonary haemorrhage, or meconium aspiration syndrome. All of these show some benefits. Most convincing to date is the trial using beractant (Survanta) in ventilated cases of meconium aspiration syndrome. Using a higher than normal dose of this surfactant (150 mg or 6 ml/kg), the trial showed improving oxygenation, and reduced air leaks, severity of pulmonary morbidity, and shorter inpatient stay among term infants.

Inhaled nitric oxide
The discovery that endothelium derived relaxing factor (EDRF) was in fact a gas, NO, has revolutionised thinking about several diseases. The NO pathway seems to have a crucial role in the vasoreactivity of the pulmonary vascular bed. PPHN may be in part due to a deficiency of or resistance to NO, and the endothelial cellular defects may represent a final common pathway for the diverse causes for PPHN.

Once suitable delivery systems were developed, inhaled NO was first tested in neonatal pilot studies and then full scale randomised controlled trials. The results of a large trial on the use of inhaled NO in full term infants with hypoxic respiratory failure were published in 1997. The trial on the use of inhaled NO in full term infants with PPHN. The results of a large scale randomised controlled trials. The results of a large trial on the use of inhaled NO in full term infants with hypoxic respiratory failure were published in 1997. The trial showed that babies who received NO were less likely to require extra corporeal membrane oxygen (ECMO). Most of these babies were pre-treated with surfactant. The dose of NO used was 20 to 80 ppm; infants who responded usually did so at the lower dose, although a few responded only to the higher dose. The results have been confirmed in further trials, which again showed no difference between doses of 5, 20, or 80 ppm. Methaemoglobinemia of greater than 7% (normally less than 1%) was more common in the group who received 80 ppm. Theoretical concerns about an increase in bleeding time have not so far translated into clinical complications.

ECMO involves oxygenating blood outside the body and providing cardiovascular support, using complex machinery resembling that used for cardiopulmonary bypass. ECMO can be used only in babies weighing more than 2 kg, and candidates for this treatment usually have PPHN or meconium aspiration syndrome. ECMO has now been used on over 11000 infants worldwide, with 80% survival reported. Traditional ECMO uses two large gauge catheters, usually one in the jugular vein and one in the carotid artery. This form of veno-arterial ECMO involves permanent sacrifice of one carotid artery, and more recently veno-venous ECMO has become more popular. While babies are on ECMO the ventilator is reduced to ‘rest’settings, allowing the lungs to recover without barotrauma. The UK collaborative ECMO trial enrolled 185 infants in two years; 30 of 93 infants allocated ECMO died com-
pared with 54 of 92 allocated conventional care. Two thirds of the cases were enrolled in the first 12 months of the trial, in 1993–94. Infants with congenital diaphragmatic hernia are an important subgroup for whom no benefit from ECMO has yet been shown, but small numbers of cases preclude a meta-analysis and some centres claim good results. Only four of the 35 infants with CDH in the UK trial survived, and all were in the ECMO arm of the trial. Concern about quality of survival remains. Forty five of 62 (73%) babies treated with ECMO in the UK trial seemed to be normal at one year of follow up. The international registry records that 17% of infants treated this way sustain an intracranial haemorrhage or infarction. A five year follow up of 103 children treated with ECMO revealed a 17% prevalence of major disability, with concern about difficult behaviour and academic failure in a higher percentage. Deafness seems to be a particular risk.

The ECMO trial began just about the time that the first babies were being treated with NO, and the numbers of neonates being offered ECMO each year in the UK is currently declining. There seems little doubt that the facility needs to be available in the UK, at a few specifically designated centres that can maintain levels of expertise because they are caring for enough cases each year. Because of the small number of ECMO centres, the difficulty for the future will be in identifying and referring appropriate cases in time. An oxygenation index of 40 or above predicted 60% mortality in the ECMO trial, and if this index does not rapidly fall with NO and/or HFOV, too much time should not be wasted in considering ECMO. Ten of the 30 deaths in the ECMO arm of the UK trial occurred among the 15 infants who were allocated to ECMO, but did not actually receive it.

### High frequency oscillation ventilation

High frequency oscillatory ventilation alternately subjects the lungs to positive and negative pressure at very fast rates, usually about 10 Hz (10 cycles per second). Special equipment is required to achieve effective ventilation at such high frequencies, and of the three oscillators available in the UK, only the Sensormedics 3100/3100A has been used in randomised controlled trials. The Sensormedics is a dedicated oscillator. The other available oscillators are the Draeger Babylog 8000 and the SLE HV2000 ventilator. Oscillators are powerful tools, and there is no doubt that in “rescue” mode HFOV can save infants with severe RDS who have failed to respond to conventional ventilation and surfactant. HFOV is particularly effective in hypercapnia. What is less certain is the role of HFOV as the primary mode of ventilation in RDS in very small babies who have received antenatal steroids and postnatal surfactant. The Provo trial randomly allocated 125 babies with RDS at less than 35 weeks of gestation who had received surfactant. Those who were ventilated with HFOV fared better than those ventilated conventionally in the short term, with more survivors without chronic lung disease at 30 days. Although there has been some concern about the high number of babies still ventilated at a month (half the HFOV group and all the conventionally ventilated group), the incidence of ultrasound abnormalities and retinopathy of prematurity was the same. Even this large study only enrolled 21 babies with a birthweight of less than 1 kg. HFOV is not the same as high frequency jet ventilation (HFJV). This involves the delivery of a jet of gas directly into the trachea, and lacks an active expiratory phase. Recent evaluations from the USA suggest an excess of cystic periventricular leucomalacia (PVL) in survivors ventilated this way. The increased risk of PVL is perhaps due to hypocapnia. A meta-analysis of trials of high frequency ventilation revealed a higher incidence of intraventricular haemorrhage and PVL which disappeared if the results of the large HiFi trial were excluded. HFOV is currently reserved for rescue treatment in most UK neonatal units, although a large MRC sponsored trial of the use of HFOV from birth in infants 26–29 weeks of gestation (the UKOS trial) is actively recruiting.

**References**

32 Marlow N. High frequency ventilation and respiratory distress syndrome: do we have an answer? *Arch Dis Child* 1998;78:F1–F2.